Levosalbutamol is a beta-2 adrenergic receptor agonist used to treat COPD and asthma. Salbutamol has been marketed as a racemic mixture, although beta2-agonist activity resides almost exclusively in the (R)-enantiomer.
- Mechanism
- Curator reviewed
β2 adrenergic receptors on airway smooth muscle are Gs coupled and their activation by levosalbutamol leads to activation of adenylate cyclase and to an increase in the intracellular concentration of 3',5'-cyclic adenosine monophosphate (cyclic AMP). Increased cyclic AMP activates protein kinase A which itself inhibits the phosphorylation of myosin produces lower intracellular ionic calcium concentrations, inducing muscle relaxation. Increased cyclic AMP concentrations are also associated with the inhibition of the release of mediators from mast cells in the airways, potentially contributing to its benefit in asthma attacks.
- Primary indication
- Indicated for the management of COPD (chronic obstructive pulmonary disease, also known as chronic obstructive lung disease) and asthma.Curator reviewed · 3 structured indications
- Formula / weight
- C13H21NO3 · 239.3107 g/mol (avg)
- First approval
- United States, 1999
- Also known as
- (R)-salbutamol · Levalbuterol · R-salbutamol
- Code names
- ASF-1096
- Brand names
Resolves to
NDAUXUAQIAJITI-LBPRGKRZSA-NSMILESCC(C)(C)NC[C@H](O)C1=CC(CO)=C(O)C=C1What you can answer from here — as of September 23, 2026
Which drugs share a target with Levosalbutamol, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account